Genotype and intensive pretreatment influence outcome of acute myeloid leukemia patients treated with venetoclax in combination with hypomethylating agents or low-dose cytarabine: "real world" data from germany
Autor/innen
- K. Braitsch
- L.K. Schmalbrock
- P. Jung
- I. Bumeder
- P. Kiewe
- J.S. Hecker
- M. Verbeek
- J. Westermann
- L. Bullinger
- U. Keller
- F. Bassermann
- J. Krönke
- K.S. Götze
- K. Rieger
Journal
- HemaSphere
Quellenangabe
- HemaSphere 6 (9): e759